New drug combo aims to stop leukemia from coming back after transplant
NCT ID NCT07493408
First seen Mar 29, 2026 · Last updated Jun 14, 2026 · Updated 13 times
Summary
This study tests whether adding asciminib to standard therapy after a stem cell transplant can help prevent leukemia from returning in people with certain types of blood cancer (Ph+ B-ALL or blastic phase CML). About 45 adults will be randomly assigned to receive either the standard drug alone or the standard drug plus asciminib. Participants will have regular clinic visits and tests to monitor for relapse and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTIC TRANSFORMATION OF CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Hong Kong
Hong Kong, Hong Kong
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.